Holen Sie sich die Stockscreener-App
1.75
1.74%
0.03
Vorhandelsmarkt:
1.73
-0.02
-1.14%
Schlusskurs vom Vortag:
$1.72
Offen:
$1.71
24-Stunden-Volumen:
580.03K
Relative Volume:
0.72
Marktkapitalisierung:
$140.74M
Einnahmen:
$63.63M
Nettoeinkommen (Verlust:
$10.62M
KGV:
35.00
EPS:
0.05
Netto-Cashflow:
$-8.64M
1W Leistung:
-4.37%
1M Leistung:
-25.21%
6M Leistung:
+9.37%
1J Leistung:
+7.36%
1-Tages-Spanne:
$1.69
$1.78
1-Wochen-Bereich:
$1.65
$1.85
52-Wochen-Spanne:
$1.32
$3.10
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Firmenname
Protalix BioTherapeutics Inc.
Sektor
Branche
Telefon
972 4 988 9488
Adresse
2 Snunit Street, Science Park PO Box 455, Karmiel
Vergleichen Sie PLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
1.75 | 138.32M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-17 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-04-04 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-04-23 | Hochstufung | Jefferies | Hold → Buy |
| 2014-11-12 | Bestätigt | R. F. Lafferty | Buy |
| 2014-01-24 | Eingeleitet | R. F. Lafferty | Buy |
| 2012-05-02 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-04-30 | Herabstufung | Auriga | Buy → Hold |
| 2011-10-13 | Eingeleitet | Morgan Joseph | Hold |
| 2011-03-17 | Herabstufung | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | Bestätigt | Oppenheimer | Outperform |
| 2010-10-14 | Bestätigt | UBS | Buy |
| 2009-12-02 | Bestätigt | Hapoalim | Outperform |
| 2009-09-22 | Eingeleitet | Canaccord Adams | Buy |
| 2009-09-02 | Eingeleitet | Hapoalim | Outperform |
| 2008-12-01 | Bestätigt | Oppenheimer | Outperform |
| 2008-03-11 | Eingeleitet | UBS | Buy |
| 2007-11-20 | Eingeleitet | CIBC Wrld Mkts | Sector Outperform |
Alle ansehen
Protalix BioTherapeutics Inc. Aktie (PLX) Neueste Nachrichten
Why analysts recommend Protalix BioTherapeutics Inc. (PBDA) stockJuly 2025 Selloffs & Detailed Earnings Play Strategies - Newser
Will Protalix BioTherapeutics Inc. (PBDA) stock rise with strong economy2025 Analyst Calls & Capital Protection Trading Alerts - Newser
How Protalix BioTherapeutics Inc. (DE) stock performs in volatility spikes2025 Short Interest & Growth Oriented Trading Recommendations - Newser
Why global investors buy Protalix BioTherapeutics Inc. (DE) stockMarket Sentiment Summary & Technical Entry and Exit Tips - Newser
Is Protalix BioTherapeutics Inc. (PBDA) stock a contrarian opportunity - Newser
Will Protalix BioTherapeutics Inc. (DE) stock split increase liquidityJuly 2025 Snapshot & Low Drawdown Momentum Trade Ideas - Newser
Why Protalix BioTherapeutics Inc. (DE) stock attracts wealthy investors2025 Market Trends & Scalable Portfolio Growth Methods - Newser
Is Protalix BioTherapeutics Inc. (DE) stock supported by strong fundamentals2025 Volume Leaders & Technical Confirmation Trade Alerts - Newser
How Protalix BioTherapeutics Inc. (PBDA) stock behaves under inflation pressure2025 Bull vs Bear & Verified Entry Point Detection - Newser
How Protalix BioTherapeutics Inc. (PBDA) stock compares with top peersJuly 2025 Selloffs & Short-Term High Return Ideas - Newser
Will Protalix BioTherapeutics Inc. (DE) stock test record highs in 2025Weekly Trade Recap & Risk Controlled Swing Alerts - Newser
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Sentiment Watch: Is Protalix BioTherapeutics Inc. stock attractive for hedge fundsCPI Data & AI Based Buy and Sell Signals - BỘ NỘI VỤ
Protalix BioTherapeutics Inc. R (PBDA.F) Q1 FY2025 earnings call transcript - Yahoo Finance
Protalix BioTherapeutics Inc. R (PBDA.F) Q2 FY2025 earnings call transcript - Yahoo Finance
Research Analysts Set Expectations for PLX FY2025 Earnings - Defense World
HC Wainwright Lowers Protalix BioTherapeutics (NYSE:PLX) Price Target to $12.00 - Defense World
PLX Analyst Forecasts - Quiver Quantitative
Protalix BioTherapeutics (PLX) Price Target Lowered by HC Wainwr - GuruFocus
HC Wainwright & Co. Maintains Protalix BioTherapeutics (PLX) Buy Recommendation - Nasdaq
Can Protalix BioTherapeutics Inc. (PBDA) stock sustain double digit ROEJuly 2025 Pullbacks & Weekly High Conviction Trade Ideas - newser.com
Is Protalix BioTherapeutics Inc. stock undervalued vs historical averagesQuarterly Profit Summary & Long Hold Capital Preservation Tips - newser.com
What RSI levels show for Protalix BioTherapeutics Inc. (PBDA) stockJuly 2025 Fed Impact & Advanced Technical Signal Analysis - newser.com
Zacks Small Cap Has Bearish Outlook for PLX FY2025 Earnings - Defense World
Will Protalix BioTherapeutics Inc. stock maintain dividend yieldJuly 2025 Decliners & Daily Entry Point Alerts - newser.com
PLX: Protalix Seeks Re-Examination of CHMP Opinion - MSN
How to integrate Protalix BioTherapeutics Inc. into portfolio analysis toolsEarnings Summary Report & Safe Capital Growth Stock Tips - newser.com
[Form 4] Protalix BioTherapeutics, Inc. Insider Trading Activity - Stock Titan
Real time scanner hits for Protalix BioTherapeutics Inc. explained2025 Stock Rankings & Safe Entry Trade Reports - newser.com
Will breakout in Protalix BioTherapeutics Inc. lead to full recovery2025 Major Catalysts & Real-Time Price Movement Reports - newser.com
How Protalix BioTherapeutics Inc. stock reacts to job market dataWeekly Gains Summary & Detailed Earnings Play Strategies - newser.com
A History of Outperforming Analyst Forecasts and Beating the Odds: Protalix BioTherapeutics Inc (PLX) - Setenews
Will Protalix BioTherapeutics Inc. stock benefit from AI adoptionDip Buying & Verified Momentum Stock Watchlist - newser.com
Finanzdaten der Protalix BioTherapeutics Inc.-Aktie (PLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):